panaloko download app for android
Quinn Ewers believes fellow Longhorns QB Arch Manning has grown and matured enough “to be able to be successful at Texas.” The Austin American-Statesman’s David Eckert called the comment “a delicate question for Ewers to answer.” “Impacted by that oblique and another ankle injury suffered later in the season, Ewers' 2024 campaign hasn't gone to plan. He's no longer projected by NFL Draft analysts to a be a first-round selection this spring. It's caused some to wonder whether he might consider returning to college for another season, and whether he'd spend that season at Texas or elsewhere,” Eckert wrote. “For months, Ewers has deflected any and all inquiries about his future intentions.” Ewers and Manning have handled the ongoing questions about who should be Texas’s rightful QB1 with grace all year. Steve Sarkisian’s plan never wavered – Ewers has kept his QB1 role and Manning has only been used in specialty packages, as many called for him to – and Texas now enters their second College Football Playoff game against Arizona State as a major favorite. Sarkisian’s legacy will be defined by how he handles these two blue-chip signal-callers. Whatever happens with Manning in the future, winning one with Ewers after making the final four-team CFP field in 2023 would make this entire situation a success. There could be a great deal of question marks if Ewers doesn’t prove capable of leading the charge in 2024. Manning has looked like a more complete QB in the limited chances he’s gotten. It’s not every year you are the No. 5 team in the country and their two losses are to the No. 2 team. The Longhorns have their best shot since Colt McCoy’s squad back in 2009 to get it done.
Cadence’s Anirudh Devgan to Present at Nasdaq Investor ConferenceREDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN ( E valuating T he E fficacy and S afety of briquilimab I n particip AN ts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma. “Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast cell activity,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper. “Following dose escalation through Part 2 of the BEACON study in CSU, we obtained regulatory clearance to move directly to a subcutaneous 180mg dose in the ETESIAN study, which we believe will drive deep mast cell depletion in the airways and enable durable clinical benefit for patients with asthma. We look forward to providing enrollment updates as we progress through the study and anticipate reporting the initial data in the second half of 2025.” The Phase 1b/2a ETESIAN study is a single dose double-blind, placebo-controlled challenge study that is expected to enroll approximately 30 patients across as many as 7 sites in Canada with a key objective of demonstrating proof-of-concept in asthma utilizing a potential therapeutic dose to inform future trials in the broader asthma population. The study will be conducted utilizing a single 180mg dose of subcutaneous briquilimab and key assessments will include both early and late asthmatic response, changes in airway hyperresponsiveness, mast cell depletion and recovery, and safety. “Depletion of mast cells via inhibition of c-Kit is a novel mechanism with the potential to alleviate asthmatic response in patients underserved by existing therapies,” said Paul O’Byrne, M.D., Professor, Dean and Vice President of the Faculty of Health Sciences at McMaster University. “As a potent and targeted c-Kit inhibitor, I believe briquilimab has the potential to overcome the safety issues that have limited development of other c-Kit inhibiting agents and, in turn, serve as an important treatment option for patients suffering from asthma. I look forward to enrolling patients into the ETESIAN study.” About Briquilimab Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and allergic asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU, and as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), Fanconi anemia (FA), and sickle cell disease (SCD). About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and asthma. To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertx.com . Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma, the potential for deep mast cell depletion in the airways and its potential ability to enable durable clinical benefit for patients with asthma; Jasper’s expectations regarding the Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, including protocols, expected patient enrollment, expected site locations, expected key objective and key assessments and expected timing to report initial data; and Jasper’s expectations regarding building out its pipeline of programs evaluating briquilimab in mast cell driven diseases. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@jaspertx.com Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@lifesciadvisors.com Lauren Walker (media) Real Chemistry 646-564-2156 lbarbiero@realchemistry.comTim Allen shares Toy Story 5 update with message to fans after 'first five-hour session'
Patriots coach Jerod Mayo believes narrow loss to Bills shows potential of his young teamI’m A Celebrity suffers very awkward tech blunder after Melvin’s exit leaving Ant McPartlin frustrated
NEW YORK — There's a Christmas Day basketball game at Walt Disney World, featuring Mickey, Minnie, Goofy and Wemby. An animated game, anyway. The real game takes place at Madison Square Garden, where Victor Wembanyama and the San Antonio Spurs face the New York Knicks in a game televised on ABC and ESPN and streamed on Disney+ and ESPN+. The special alt-cast, the first animated presentation of an NBA game, will be shown on ESPN2 and also stream on Disney+ and ESPN+. Madison Square Garden is a staple of the NBA's Christmas schedule. Now it merges with a bigger home of the holidays, because the "Dunk the Halls" game will be staged at Disney, on a court set up right smack in the middle of where countless families have posed for vacation photos. Why that location? Because it was Mickey Mouse's Christmas wish. "Basketball courts often have the ability to make a normal environment look special, but in Disney it can only turn out incredible," Wembanyama said in an ESPN video promoting his Christmas debut. The story — this is Disney, after all — begins with Mickey penning a letter to Santa Claus, asking if he and his pals can host a basketball game. They'll not only get to watch one with NBA players, but some of them will even get to play. Goofy and Donald Duck will sub in for a couple Knicks players, while Mickey and Minnie Mouse will come on to play for the Spurs. "It looks to me like Goofy and Jalen Brunson have a really good pick-and-roll at the elite level," said Phil Orlins, an ESPN vice president of production. Walt Disney World hosted real NBA games in 2020, when the league set up there to complete its season that had been suspended by the COVID-19 pandemic. Those games were played at the ESPN Wide World of Sports. The setting for the Christmas game will be Main Street USA, at the entrance of the Magic Kingdom. Viewers will recognize Cinderella's castle behind one baseline and the train station at the other end, and perhaps some shops they have visited in between. Previous alternate animated broadcasts included an NFL game taking place in Andy's room from "Toy Story;" the "NHL Big City Greens Classic" during a game between the Washington Capitals and New York Rangers; and earlier this month, another NFL matchup between the Cincinnati Bengals and Dallas Cowboys also taking place at Springfield's Atoms Stadium as part of "The Simpsons Funday Football." Unlike basketball, the players are helmeted in those sports. So, this telecast required an extra level of detail and cooperation with players and teams to create accurate appearances of their faces and hairstyles. "So, this is a level of detail that we've never gone, that we've never done on any other broadcast," said David Sparrgrove, the senior director of creative animation for ESPN. Wembanyama, the 7-foot-3 phenom from France who was last season's NBA Rookie of the Year, looks huge even among most NBA players. The creators of the alternate telecast had to design how he'd look not only among his teammates and rivals, but among mice, ducks and chipmunks. "Like, Victor Wembanyama, seeing him in person is insane. It's like seeing an alien descend on a basketball court, and I think we kind of captured that in his animated character," said Drew Carter, who will again handle play-by-play duties, as he had in the previous animated telecasts, and will get an assist from sideline reporter Daisy Duck. Wembanyama's presence is one reason the Spurs-Knicks matchup, the leadoff to the NBA's five-game Christmas slate, was the obvious choice to do the animated telecast. The noon EST start means it will begin in the early evening in France and should draw well there. Also, it comes after ABC televises the "Disney Parks Magical Christmas Day Parade" for the previous two hours, providing more time to hype the broadcast. Recognizing that some viewers who then switch over to the animated game may be Disney experts but NBA novices, there will be 10 educational explainers to help with basketball lingo and rules. Beyond Sports' visualization technology and Sony's Hawk-Eye tracking allow the animated players to make the same movements and plays made moments earlier by the real ones at MSG. Carter and analyst Monica McNutt will be animated in the style of the telecast, donning VR headsets to experience the game from Main Street, USA. Other animated faces recognizable to some viewers include NBA Commissioner Adam Silver, who will judge a halftime dunk contest among Mickey and his friends, and Santa himself, who will operate ESPN's "SkyCam" during the game. The players are curious how the production — and themselves — will look. "It's going to be so crazy to see the game animated," Spurs veteran Chris Paul said. "I think what's dope about it is it will give kids another opportunity to watch a game and to see us, basically, as characters." Get local news delivered to your inbox!
2024 was a big year for discontinuations. Not only were several long-running models axed, but an entire brand – Citroen – announced it was pulling up stumps. While it wasn’t quite the massacre that 2020 was (when Holden and Infiniti shut up shop) or 2021 (when a new Australian Design Rule killed off several popular models), this year saw plenty of high-profile axings. 100s of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now . Ford killed one of its last remaining SUVs in Australia, Toyota officially pulled the plug on its V8-powered LandCruiser 70 Series, and global production ended for a raft of Jaguar and Maserati models. We’ve split up this year’s casualties into two articles: one focusing on the SUVs and utes discontinued this year, and one focusing on the passenger cars. Scroll below for all the SUVs and utes axed this year, or click on one of the links below to take you directly to a retired model. The C5 Aircross was Citroen’s best-selling vehicle in Australia, but that’s not saying much. Just 53 examples of the mid-sized SUV, related to the Peugeot 3008 , were sold this year to the end of November. While that’s up from last year’s tally, it still puts the Citroen dead last in its segment, with Peugeot selling more than six times as many 3008s – itself not a huge seller. Between its local launch in 2019 and the end of November, Citroen sold just 350 C5 Aircross SUVs in Australia. Not helping the niche Toyota RAV4 rival was Citroen’s limited dealer network, as well as a limited lineup. A 2023 facelift brought not only visual tweaks but also an upgraded powertrain. Still using a turbocharged 1.6-litre four-cylinder petrol engine, the updated model substituted the six-speed automatic for an eight-speed, gaining 12kW and 10Nm for total outputs of 133kW and 250Nm. However, the facelift brought with it a price increase, and Citroen sales had dwindled so much over the years that it could scarcely afford to charge a premium over more mainstream brands. There’s a new generation of C5 Aircross coming to Europe, but it won’t be boarding the ship here as the Citroen brand was retired this year. MORE: Citroen leaving Australia after more than 100 years, importer focusing on Peugeot MORE: Everything Citroen C5 Aircross This cat didn’t have nine lives. The Ford Puma lives on in Europe, where it’s been treated to a facelift and was even joined by an electric version called the Gen-E . The Puma Gen-E was supposed to come here, but Ford Australia recently cancelled its plans . “There are many factors that influence whether a vehicle’s business case stacks up – such as economic trends, material costs, consumer incentives and global supply chain – and after weighing these up, we took the call that we were better to focus our electrified lineup on other models,” said Ford Australia early in December. As for the facelifted combustion-powered Puma, Ford Australia made no such commitment to bring it here. In axing the Puma in February this year, shortly before the reveal of the facelifted model, Ford Australia said it hadn’t made the decision lightly but had decided to focus on commercial vehicles and the Mustang family. This follows last year’s announcement from the Blue Oval that the mid-sized Escape would also be axed, so the facelifted version of Ford’s Toyota RAV4 rival never ended up coming here either. Axing the Escape laves Ford without an entrant in Australia’s largest segment by volume, while axing the Puma sees the brand without a traditional entry-level model to attract people to the brand. The most affordable Ford is now the single-cab/chassis Ranger, while the Blue Oval’s most affordable SUV is the circa-$54,000 Everest – which costs close to twice the price of the defunct Puma, which opened at just over $30,000 before on-roads. While the Puma sold in similar numbers to the Escape, it commanded a greater share of the less competitive light SUV segment. It comfortably outsold the Renault Captur and Nissan Juke in recent years, though rivals like the Hyundai Venue and Toyota Yaris Cross outsold it by around three-to-one. That was despite the Puma being quite a good thing. It launched here in 2020 as a replacement for the unloved Ecosport , a light SUV initially designed for developing markets. The Puma shared its platform with the Fiesta , and was widely regarded as a genuinely good steer like its hatchback sibling. Sadly, we never got the more powerful ST version here, with all Pumas instead featuring a 92kW/170Nm turbocharged 1.0-litre three-cylinder engine mated with a seven-speed dual-clutch automatic transmission. Ford sold 597 examples of the Puma that year, growing to 3218 in 2021, but this slipped to 2408 sales in 2022 and then 2027 sales in 2023. To the end of November this year, Ford sold 839 examples as it ran out remaining stock. Ford’s local SUV lineup here now consists solely of the electric Mustang Mach-E and the diesel-powered Everest. MORE: Ford Australia kills its most affordable vehicle in favour of vans, electric cars MORE: Everything Ford Puma It’s not often a brand axes almost its entire lineup without also being shuttered itself, but that’s just what has happened at Jaguar. The British brand’s attempts this century to take on BMW and Mercedes-Benz directly, first with the S-Type and X-Type and more recently with its current lineup of sedans and SUVs, have come to nought. Jaguar executives themselves have said the brand today has “no equity whatsoever”. Yikes. Jaguar is reinventing itself as a more exclusive, more expensive, electric-only brand, which means chip chip cheerio to the current F-Type sports car, the E-Pace , F-Pace and I-Pace SUVs, and the XE and XF sedans. Piecing together what is being retired when, however, is a little complicated. Vehicles built in the Castle Bromwich plant in the UK – the F-Type, XE and XF – all ended production earlier this year. Overseas reports have subsequently indicated the E-Pace and I-Pace, built by Magna Steyr in Austria, were also exiting production this year, with the UK-built F-Pace reportedly getting a stay of execution until 2025 or 2026. The F-Pace arguably is the more impressive of Jaguar’s two combustion-powered SUVs, not just because it can be had in hot supercharged V8 SVR guise, but because all models have largely aluminium construction. This means despite being larger, the F-Pace weighs essentially the same as the E-Pace – comparing P250 models, there’s a difference of around 40kg. While the F-Pace shares its rear/all-wheel drive platform with the Range Rover Velar , the E-Pace features the same front/all-wheel drive underpinnings as the Range Rover Evoque . It entered production in 2017, around a year after the F-Pace, and arrived here in 2018. Jaguar offered a range of petrol and diesel powertrains during the E-Pace’s run, though Australia missed out on plug-in hybrid power (something the local-spec F-Pace has finally received). The E-Pace became Jaguar’s best-seller locally, at least until 2022 when the F-Pace took the lead. Parent JLR was prioritising production of more upmarket, higher-margin models during this time, and sales of the E-Pace and its Range Rover Evoque and Land Rover Discovery Sport platform-mates all dropped around this time. To the end of November 2024, Jaguar sold 3710 E-Paces in Australia during its run. But while it may have been the brand’s best-seller for several years, it lived in the shadow of its Range Rover Evoque cousin, which has consistently outsold it – not to mention its German SUV rivals, which left it in the dust. Jaguar is expected to still offer an SUV in its new, more exclusive, electric-only era, but it won’t be as accessible as the E-Pace. MORE: Everything Jaguar E-Pace You can’t accuse Jaguar of being late to the EV game. The Jaguar I-Pace first entered production in 2018, before other premium brands like Lexus, Maserati and Volvo, among others, would enter the EV space. And while the first EV efforts of some premium brands were based on combustion-powered models, the I-Pace debuted a dedicated EV platform and featured futuristic and yet distinctively Jaguar styling penned under former design boss Ian Callum. Critical acclaim was immense, with the I-Pace winning various awards including European Car of the Year. And yet despite the effort Jaguar went to, the I-Pace is being discontinued without a replacement like the rest of the brand’s current lineup. Where BMW’s first EV, the i3, was a quirky city car, the I-Pace targeted the mid-sized SUV market, the volume-selling space where models like the BMW iX3 and Lexus RZ now dwell. Like the BMW i3 , however, the I-Pace’s platform never underpinned anything else. But where BMW eventually rolled out other EVs, the I-Pace remained Jaguar’s only EV. It has proved a rather disappointing seller for the British brand, peaking in 2019 with 17,355 sales globally. I-Pace sales have continued to decline since then, with sales dropping to around 7000 units last year. In Australia, it has been a virtual non-entity. From a height of 155 sales in 2019, Jaguar sold just 23 examples here in 2022. From its 2018 launch until the end of November this year, Jaguar has sold 377 examples in Australia. Updates during its run were minor – a new infotainment system in 2020, and minor visual tweaks for model year 2024. Even as the I-Pace comes to its end, it still packs the same powertrain as it did at launch: a 294kW/696Nm dual-motor all-wheel drive powertrain powered by a 90kWh lithium-ion battery. Range is a claimed 446km on the NEDC cycle and the DC fast-charge rate is 104kW, figures that were much more impressive in 2018 than they are today. The I-Pace has also suffered from an increasingly large range of rivals, with even Cadillac launching in Australia’s luxury electric SUV fray. MORE: Everything Jaguar I-Pace The Maserati Levante is another model that technically remains on price lists, but which ended production this year. Maserati revealed the Kubang concept car at the 2011 Frankfurt motor show, which previewed what would become the Trident brand’s first SUV. The Levante didn’t debut until the 2016 Geneva motor show, riding the M156 platform of the Ghibli and Quattroporte sedans. The Porsche Cayenne had been seen as sacrilegious by fans of the German brand at launch, but by the time Maserati put its trident badge on an SUV the controversy had calmed. Launched here in 2017, the Levante went up against the Cayenne and, until the smaller Grecale arrived in 2023, it was Maserati’s most affordable model and its only SUV. A variety of powertrains were offered during the Levante’s run, including twin-turbocharged V6 and V8 petrol engines, a turbo-diesel V6, and a turbocharged four-cylinder mild-hybrid. However, all Levantes were all-wheel drive and used an eight-speed automatic transmission. Unlike the Cayenne, the Levante was never offered with plug-in hybrid power. The highlight of the Levante range was the twin-turbo 3.8-litre V8 developed and supplied by Ferrari, which powered the GTS and later Trofeo versions of the large SUV. The latter had outputs of 427kW and 730Nm. From first registrations in 2016 to the end of November 2024, Maserati sold 2342 Levantes in Australia. Over the same period Porsche sold just over five times as many Cayennes. Its best year was actually towards the end – 2022, when Maserati sold 436 examples. That saw it outsell the Audi Q8 (423 sales), Jaguar F-Pace (316), and Range Rover Velar (319). The Levante and its Quattroporte sibling are set to be replaced by electric vehicles (EVs). However, Maserati confirmed earlier this year that these won’t arrive until 2027 and 2028, respectively. From 2028, Maserati plans to only sell EVs, though it’s unclear if this will change now that the CEO of parent company Stellantis, Carlos Tavares, has stepped down. Stellantis’ new family of STLA-branded platforms support multiple propulsion types, so a petrol-powered next-generation Levante isn’t completely out of the question. Just don’t expect it to pack a sweet V8 like the outgoing model. MORE: Everything Maserati Levante After launching a 2.8-litre turbo-diesel four-cylinder automatic version of the iconic LandCruiser 70 Series in 2007, Toyota officially axed the long-running ‘1VD-FTV’ 4.5-litre turbo-diesel V8 manual option in July. However, with a long order list to get through after orders had been paused for two years, Toyota said the V8-powered 70 Series wasn’t disappearing just yet. It said production of V8-powered 70 Series models would end in September 2024, except for 79 Series GXL single- and double-cab utes, with final deliveries of V8-powered wagons, Troop Carriers, and Workmate and GX utes due this year. Production of GXL utes, in contrast, is set to continue “well into next year”, with customer deliveries to be completed during the fourth quarter of 2025. Between 2007 and June 2024, Toyota says it sold more than 171,010 V8-powered 70 Series vehicles in Australia. So why kill the 70 Series V8 now, when it appears as sought-after as ever? In July, Toyota Australia vice president of sales, marketing and franchise operations, Sean Hanley, said that while the incoming New Vehicle Efficiency Standard (NVES) played a part, it was “consumer sentiment” that played the biggest role. Toyota Australia claims it was a “joint decision” between it and head office in Japan. If you want to place an order for a new 70 Series, you’ll have to settle for one powered by the same 2.8-litre turbo-diesel as the HiLux and Prado (but without mild-hybrid tech), though it will comewith something the V8 never did – an automatic transmission. Not only that, the four-cylinder 70 Series actually makes 70Nm more torque at 500Nm, while being just 1kW less powerful at 150kW. MORE: Everything Toyota LandCruiser 70 Series MORE: Why ‘community sentiment’ helped kill Toyota’s V8 4WD, but not its US pickup MORE: Toyota LandCruiser 70 Series V8 axed, but manual will live on MORE: Every car and SUV discontinued in Australia in 2023 MORE: Every car discontinued in 2022 MORE: Every car discontinued in 2021 MORE: The cars we lost in 2020Dividend, bonus, stock split: Redtape to trade ex-dividend, KPI Green Energy to trade ex-bonus next week; Full list
ERES Provides Update On Previously Disclosed Strategic TransactionsSAN FRANCISCO , Nov. 22, 2024 /PRNewswire/ -- RapidTranslate.org announces the strategic integration of three leading language resource platforms into its comprehensive translation services ecosystem. The company has partnered with Languages Without Limits ( www.languageswithoutlimits.co.uk ), Workshop on Immigrant Languages ( www.workshoponimmigrantlanguages.org ), and Arctic Languages ( www.arcticlanguages.com ) to enhance its educational and research offerings while maintaining these platforms' valuable existing resources. This integration coincides with RapidTranslate.org 's significant expansion into the European market, where the company now provides certified translations in over 60 languages across Germany , France , Spain , Italy , and the United Kingdom . This dual focus on educational resources and certified translations reinforces RapidTranslate.org 's position as a trusted global language services provider. Key Highlights of RapidTranslate.org 's Offerings: Comprehensive Language Support: Enhanced educational and research resources through the integration of three respected language platforms, serving educators, researchers, and language enthusiasts worldwide. Certified Translations: Professional translation services for official and legal documents, backed by a 100% USCIS acceptance guarantee. Global Reach: Expanded European presence supporting individuals, families, businesses, and professionals across key markets. A Leader in Certified Translations RapidTranslate.org delivers professional translations for immigration documentation, legal submissions, business contracts, and academic records. Every document is processed by experienced human translators to ensure linguistic and cultural accuracy. Services include: "By creating a centralized hub for both language resources and certified translation services, we're meeting the evolving needs of our increasingly connected world," says CEO and founder of RapidTranslate.org . "Our expansion into Europe represents our commitment to providing accessible, professional language services to a global audience." Supporting a Multilingual World RapidTranslate.org continues to advance its mission of fostering global communication through its combination of advanced technology and professional human expertise. With over 350,000 successfully translated documents and a growing repository of language learning resources, RapidTranslate.org remains dedicated to quality, security, and accessibility in language services. About RapidTranslate.org Founded in 2020, RapidTranslate.org has grown from a specialized translation service to a comprehensive language solutions provider. The company serves clients ranging from individual immigrants to Fortune 500 companies, maintaining the highest standards of accuracy and security in document translation while advancing language education and research. Connect with RapidTranslate.org : Website: www.rapidtranslate.org View original content: https://www.prnewswire.com/news-releases/rapidtranslateorg-centralizes-language-resources-and-expands-certified-translation-services-globally-302314613.html SOURCE Rapid Translate
AE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adams Resources & Energy, Inc. Is Fair to ShareholdersPowell will 'cut to appear to not be political' against TrumpMickey, Minnie, Goofy and Wemby
By MICHELLE L. PRICE NEW YORK (AP) — Chad Chronister, Donald Trump’s pick to run the Drug Enforcement Administration, said Tuesday he was withdrawing his name from consideration, becoming the second person selected by the president-elect to bow out quickly after being nominated for a position requiring Senate confirmation. Sheriff Chronister, the top law enforcement officer in Hillsborough County, Florida, said in a post on X that he was backing away from the opportunity, which he called “the honor of a lifetime.” “Over the past several days, as the gravity of this very important responsibility set in, I’ve concluded that I must respectfully withdraw from consideration,” Chronister wrote. He did not elaborate, and Trump’s transition team did not immediately respond to a message seeking comment. Chronister follows former Republican congressman Matt Gaetz , Trump’s first pick to serve as attorney general, in withdrawing his name for a post in the administration. Gaetz withdrew following scrutiny over a federal sex trafficking investigation that cast doubt on his ability to be confirmed as the nation’s chief federal law enforcement officer. Trump’s pick of Chronister for the DEA job drew backlash from conservatives, who raised concerns over his actions during the COVID-19 pandemic and his saying that his office “does not engage in federal immigration enforcement activities.” In March 2020, Chronister arrested the pastor of a megachurch who held services with hundreds of people and violated a safer-at-home order in place aimed at limiting the spread of the Covid virus. “Shame on this pastor, their legal staff and the leaders of this staff for forcing us to do our job. That’s not what we wanted to do during a declared state of emergency,” Chronister said at the time. “We are hopeful that this will be a wakeup call.” U.S. Rep. Thomas Massie, R-Ky, was among those airing public complaints, saying Chronister should be “disqualified” for the arrest. Others flagged comments Chronister made in a video about Florida’s immigration laws that he released in 2023 that circulated again online after Trump named him last weekend. Related Articles National Politics | Trump team signs agreement to allow Justice to conduct background checks on nominees, staff National Politics | President-elect Donald Trump’s lawyers urge judge to toss his hush money conviction National Politics | Democrats stick with Schumer as leader, their strategy for countering Trump is far less certain National Politics | Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs National Politics | Democrats’ outgoing chair says Trump’s win forces party to reassess how it reaches voters In the video, Chronister praised the “rich diversity” of his community and called it “a place where people from all walks of life come together.” He said it was important to note his office “does not engage in federal immigration enforcement activities. We do not target individuals based on their immigration status. That’s the authority of federal agencies.” Trump has made a sweeping crackdown on immigration a central focus of his campaign and his aims for his coming administration. Associated Press writer Adriana Gomez Licon in Fort Lauderdale, Florida contributed to this report. Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Most Popular German restaurant Deutsche Ecke opens in Newport News German restaurant Deutsche Ecke opens in Newport News Second man dies in Newport News triple shooting; police still looking for suspects Second man dies in Newport News triple shooting; police still looking for suspects The latest business openings and closings in Hampton Roads The latest business openings and closings in Hampton Roads Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Former Hampton High football coach Mike Smith highlights latest Virginia Hall of Fame inductees Williamsburg Christmas parade to feature Commanders marching band Williamsburg Christmas parade to feature Commanders marching band Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap Al Roker speaks out after Macy’s Thanksgiving Day Parade chair mishap 1 dead, 2 seriously injured in Newport News triple shooting, police say 1 dead, 2 seriously injured in Newport News triple shooting, police say New Kent wants public input on future of Makemie Woods New Kent wants public input on future of Makemie Woods The Grinch can’t steal West Point’s Christmas The Grinch can't steal West Point's Christmas Biden pardons his son Hunter despite previous pledges not to Biden pardons his son Hunter despite previous pledges not to Trending Nationally Judge accused of ‘willful misconduct’ for letting illegal immigrant escape court Trump’s talk of reducing or relocating federal workers hits home in Maryland A young Coloradan learning to live with long COVID turns to TikTok to educate about chronic illness Fruit trees and ‘generational learning’ turn this California city into a parrot paradise as temperatures drop NBC’s enhanced yard lines, field numbers for Bills-49ers snow game draw strong reactions from viewersBy MICHELLE L. PRICE NEW YORK (AP) — Chad Chronister, Donald Trump’s pick to run the Drug Enforcement Administration, said Tuesday he was withdrawing his name from consideration, becoming the second person selected by the president-elect to bow out quickly after being nominated for a position requiring Senate confirmation. Sheriff Chronister, the top law enforcement officer in Hillsborough County, Florida, said in a post on X that he was backing away from the opportunity, which he called “the honor of a lifetime.” “Over the past several days, as the gravity of this very important responsibility set in, I’ve concluded that I must respectfully withdraw from consideration,” Chronister wrote. He did not elaborate, and Trump’s transition team did not immediately respond to a message seeking comment. Chronister follows former Republican congressman Matt Gaetz , Trump’s first pick to serve as attorney general, in withdrawing his name for a post in the administration. Gaetz withdrew following scrutiny over a federal sex trafficking investigation that cast doubt on his ability to be confirmed as the nation’s chief federal law enforcement officer. Trump’s pick of Chronister for the DEA job drew backlash from conservatives, who raised concerns over his actions during the COVID-19 pandemic and his saying that his office “does not engage in federal immigration enforcement activities.” In March 2020, Chronister arrested the pastor of a megachurch who held services with hundreds of people and violated a safer-at-home order in place aimed at limiting the spread of the Covid virus. “Shame on this pastor, their legal staff and the leaders of this staff for forcing us to do our job. That’s not what we wanted to do during a declared state of emergency,” Chronister said at the time. “We are hopeful that this will be a wakeup call.” U.S. Rep. Thomas Massie, R-Ky, was among those airing public complaints, saying Chronister should be “disqualified” for the arrest. Others flagged comments Chronister made in a video about Florida’s immigration laws that he released in 2023 that circulated again online after Trump named him last weekend. Related Articles National Politics | Trump team signs agreement to allow Justice to conduct background checks on nominees, staff National Politics | President-elect Donald Trump’s lawyers urge judge to toss his hush money conviction National Politics | Democrats stick with Schumer as leader, their strategy for countering Trump is far less certain National Politics | Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs National Politics | Democrats’ outgoing chair says Trump’s win forces party to reassess how it reaches voters In the video, Chronister praised the “rich diversity” of his community and called it “a place where people from all walks of life come together.” He said it was important to note his office “does not engage in federal immigration enforcement activities. We do not target individuals based on their immigration status. That’s the authority of federal agencies.” Trump has made a sweeping crackdown on immigration a central focus of his campaign and his aims for his coming administration. Associated Press writer Adriana Gomez Licon in Fort Lauderdale, Florida contributed to this report.Stock market today: Rising tech stocks pull Wall Street to another record
UBS starts coverage on gov service providers stock amid spending uncertainty